Dr Laura Pina VegasRhumatologue à Créteil

Praticien hospitalier

Appeler· 01 49 81 21 11 Rechercher sur Doctolib

Photo : Suaudeau, CC BY-SA 4.0, Wikimedia Commons

Vous êtes Dr Laura Pina Vegas ? Présentation, expertises, actes, site du cabinet : faites de cette fiche la page de votre cabinet.

Configurer votre fiche gratuitement →

Dr Laura Pina Vegas est rhumatologue à Créteil (94010). Il consulte à GHU APHP HM SITE HENRI MONDOR, 51 Avenue MAL DE LATTRE DE TASSIGNY, 94010 Créteil.

Enregistrer le contact

publications: 36publications
citations: 587citations

Consulter

Lieu de consultation

GHU APHP HM SITE HENRI MONDOR
51 Avenue MAL DE LATTRE DE TASSIGNY, 94010 Créteil
Hospitalier

Dr Laura Pina Vegas, c'est vous ?

Faites de cette fiche la page de votre cabinet.

Votre présentationQuelques lignes sur votre pratique, affichées en tête de page.
Vos domaines d'expertiseLes pathologies que vous suivez, à la place des domaines déduits.
Vos actesÉchographie, infiltrations, viscosupplémentation, PRP, téléexpertise.
Vos liensSite du cabinet, LinkedIn, secteur de conventionnement corrigé.

Configurer votre fiche gratuitementGratuit · réservé au praticien

Formation

Parcours et diplômes (9)

DES

DES Rhumatologie · Rhumatologie (SM) — Diplôme d'études spécialisées

CES

DE Docteur en médecine — Capacité / certificat d'études spéciales

2026
Inserm
2020–2026
Université Paris-Est Créteil
2024–2026
Leiden University Medical Center
2020–2026
Centre Hospitalier Universitaire Henri-Mondor
2025
Toronto Western Hospital
2025
University of Oxford
Affiliations déclarées dans les publications (OpenAlex).

En bref

Questions fréquentes sur Dr Laura Pina Vegas

Où consulte Dr Laura Pina Vegas ?

Dr Laura Pina Vegas consulte à GHU APHP HM SITE HENRI MONDOR, 51 Avenue MAL DE LATTRE DE TASSIGNY, 94010 Créteil. Adresses issues de l'Annuaire Santé (ANS).

Comment prendre rendez-vous avec Dr Laura Pina Vegas ?

Par téléphone au 01 49 81 21 11 (numéro publié à l'Annuaire Santé). Un lien de recherche Doctolib est proposé sur cette page : si le praticien y est inscrit, son profil figure normalement parmi les résultats.

D'où viennent les informations de cette page ?

Identité, diplômes et lieux d'exercice : Annuaire Santé (ANS, licence ouverte). Conventionnement et carte Vitale : Assurance Maladie. Publications : bases scientifiques publiques (PubMed, HAL, OpenAlex), affichées seulement si le nom du praticien figure parmi les auteurs. Le praticien peut corriger sa fiche ou en demander le retrait à tout moment ; en cas d'homonymie, signalez-le.

Rhumatisme psoriasique · 12

2026Rheumatology and therapyPubMed

Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials

2024RMD openPubMed

Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS)

2024Rheumatology (Oxford, England)PubMed

Comparison of biologics in psoriatic arthritis: an important clinical issue

2024RMD openPubMed

Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)

2023RMD openPubMed

Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)

2022RMD openPubMed

Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)

2022Rheumatology (Oxford, England)PubMed

Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply

2022Rheumatology (Oxford, England)PubMed

Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply

2022JAMA dermatologyPubMed

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database

2022Rheumatology (Oxford, England)PubMed

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study

2021The British journal of dermatologyPubMed

Head-to-head trials in psoriasis and psoriatic arthritis: how to conclude?

2021Rheumatology (Oxford, England)PubMed

Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database

Spondyloarthrite · 11

2026Joint bone spinePubMed

Comment on: "The effect of alcohol consumption on clinical outcomes and structural damage in patients with axial spondyloarthritis: A systematic literature review and meta-analysis. Joint Bone Spine 2025;92(1):105794" by Gendron et al

2026Joint bone spinePubMed

Preconception, pregnancy and postpartum periods in spondyloarthritis: Unmet needs and challenges from a patients and rheumatologists surveys

2026Arthritis & rheumatology (Hoboken, N.J.)PubMed

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

2026RMD openPubMed

Influence of initial axial involvement on the phenotypic evolution of axial spondyloarthritis: 10-year data from the DESIR cohort

Transversal · 7

2026Joint bone spinePubMed

A new biochemical score from synovial fluid for diagnosing septic arthritis

2025Clinical and experimental dermatologyPubMed

Recurrences and rechallenges of suspected drugs in patients with epidermal necrolysis

2024Journal of clinical medicinePubMed

Value of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Identifying Osteoarticular Septic Grafts in Suspected Infective Endocarditis: Results from a Large Monocentric Cohort

2023Joint bone spinePubMed

PET/CT for osteoarticular septic grafts in endocarditis: A large monocentric cohort

Polyarthrite rhumatoïde · 3

2024RMD openPubMed

Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide study

2023Annals of the rheumatic diseasesPubMed

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

2023Joint bone spinePubMed

Prevalence, mortality, and treatment of patients with rheumatoid arthritis: A cohort study of the French National Health Data System, 2010-2019

Anti-IL-23 · 1

2026Rheumatology and therapyPubMed

Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials

Anti-TNF · 1

2023Annals of the rheumatic diseasesPubMed

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Case report / série · 1

2026Joint bone spinePubMed

Infectious pubic symphysitis after prostate cancer treatment: A retrospective case series of 16 patients

Comorbidités · 1

2023The British journal of dermatologyPubMed

Trajectories of comorbidities in patients with psoriasis: a question to be answered

IA en rhumatologie · 1

2025RMD openPubMed

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

Infiltrations · 1

2022International journal of rheumatic diseasesPubMed

Horner syndrome after cervical spine corticosteroid injection

IRM ostéo-articulaire · 1

2023Rheumatology (Oxford, England)PubMed

Structural changes in the sacroiliac joint imaging in axial spondyloarthritis: from conventional radiography to magnetic resonance imaging?

JAK inhibiteurs · 1

2023Annals of the rheumatic diseasesPubMed

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Dr Laura Pina VegasRhumatologue à Créteil

Lieu de consultation

Préparer votre rendez-vous

Conventionnement et remboursement

Expertise et points clés

Parcours et diplômes (9)

Travaux scientifiques (45)

Questions fréquentes sur Dr Laura Pina Vegas

Où consulte Dr Laura Pina Vegas ?

Comment prendre rendez-vous avec Dr Laura Pina Vegas ?

D'où viennent les informations de cette page ?

Rhumatologues à Créteil et alentours